Mazen Noureddin describes how he became engaged in studying the cost-effectiveness of widespread NASH screening for diabetics in the US, and what he has found, while the Surfers comment on the value of this pivotal work.
This conversation integrates two significant side conversations during the review of the NASH-TAG 2021 agenda, one about creativity and intellectual ferment and the other about what we can learn from COVID-19 about how to motivate patients.
Stephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12
The panel explores three less obvious ways that the COVID-19 pandemic has affected ability to recruit the right patients into clinical trials
Donna Cryer joins the Surfers to explore efforts to support residents in disadvantaged minority communities in the US, UK and Australia in improving their Liver Health and awareness.
The Surfers end this episode by discussing the need for public education to create the awareness necessary for change
Evaluating the economic and patient-motivating value of enhanced telemedicine and mobile non-invasive testing technologies in improving NAFLD diagnosis and lowering rates of non-communicable disease
Innovations in Telemedicine and Mobile Technologies are already changing patient care in ways that will remain and expand in the “New Normal” after the COVID-19 pandemic is less urgent
Manal Abdelmalek joins the Surfers to describe long-term changes in patient management that improved diagnostic and telecommunication technologies can drive in response to new COVID-19 induced challenges
The discussion turns toward a question: if NALFD patients have poorer COVID-19 prognoses, how can we use this fact to drive broader population-based screening?
